جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

This study is investigating a medicine called ritlecitinib for treating alopecia areata, a condition causing hair loss. Ritlecitinib is already approved in some countries at a 50mg dose. This study will compare that dose with a higher 100mg dose to see if it's also safe and effective. Researchers want to find out if the 100mg dose helps hair grow back and if it has any side effects. Participants, aged 12 and older with significant scalp hair loss due to alopecia areata, will take part. They will be randomly assigned to receive one of the doses, or a dummy pill (placebo), and will be observed for about 13 months with regular check-ups.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
فايزر
الهدف من التسجيل
674
ابدأ
01 أبريل 2025
التاريخ المتوقع للانتهاء
19 Mar 2028

ما هو موضوع هذه الدراسة؟

Alopecia areata is a common condition where the immune system mistakenly attacks hair follicles, leading to hair loss on the scalp, face, and sometimes other parts of the body. While there are some treatments available, researchers are always looking for new and effective options.

This particular study is focusing on a medicine called ritlecitinib. It's designed to help calm down the immune system's overreaction that causes hair loss. A 50mg dose of ritlecitinib is already used in many countries for severe alopecia areata in people aged 12 and above. Now, doctors want to see if a higher 100mg dose might be even more effective, while still being safe.

The main goal of this study is to compare the 50mg and 100mg doses of ritlecitinib. They want to check how well both doses work in helping hair grow back, as well as keeping a close eye on any potential side effects. By carefully studying these two doses, researchers hope to better understand the best way to use ritlecitinib to help people living with alopecia areata.

النقاط الرئيسية

  • This study evaluates two doses (50mg and 100mg) of ritlecitinib for alopecia areata.
  • Ritlecitinib aims to help hair regrowth by addressing the immune system.
  • Participants will be aged 12 and older with significant scalp hair loss.
  • The study lasts about 13 months with regular clinic visits.
  • You will be randomly assigned to receive ritlecitinib or a placebo.
  • Participation includes various health checks and questionnaires.

من قد يكون مؤهلاً؟

To join this study, you need to be at least 12 years old and have a clear diagnosis of alopecia areata. This means your doctor has confirmed your hair loss is due to this specific condition, and not something else. You must also have lost at least half of the hair on your scalp.

It's important that your hair loss specifically due to alopecia areata and not another medical issue. Also, your current episode of hair loss shouldn't have started more than 10 years ago. You must be willing to stop any other alopecia areata treatments you're currently using while you're in the study.

There are also some reasons why you might not be able to join. For example, if you have other conditions that cause hair loss, a history of serious allergic reactions to similar medicines, or certain infections, you might not be eligible. The study team will discuss all these details with you thoroughly to make sure taking part is safe and suitable for you.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you 12 years of age or older?
  2. Have you been diagnosed with alopecia areata?
  3. Have you lost 50% or more of the hair on your scalp?
  4. Is your current hair loss episode 10 years old or less?
  5. Are you willing to stop any other alopecia areata treatments if you join?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join this study, you'll be involved for about 13 months. During this time, you'll be asked to visit the study clinic up to 9 times. When you join, you'll be randomly assigned, like drawing names out of a hat, to receive one of the two doses of ritlecitinib (50mg or 100mg), or a dummy pill called a placebo. You'll take your assigned medicine by mouth once a day.

During your visits, the study team will carry out several checks. These will include assessing your hair loss, having physical examinations, hearing tests, and blood tests. You might also have an X-ray and an ECG (a test that checks your heart's electrical activity). They'll take photographs of your scalp and eyes to track any changes. You'll also be asked to fill in some questionnaires about your alopecia areata and how you're feeling.

المخاطر والفوائد المحتملة

Taking part in a clinical study can offer potential benefits, such as access to a new treatment before it's widely available and contributing to medical knowledge that could help others. However, there are also potential risks, as with any medication. You might experience side effects from the study medicine, or the treatment might not work for you. There will also be appointments and tests that take up your time. It's very important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (148)

  • The Kirklin Clinic of UAB Hospital (Radiology)
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • University of Alabama at Birmingham Faculty Office Towers (Regulatory)
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • جامعة ألاباما في برمنغهام
    الرمز البريدي المؤكد
    برمنغهام، الولايات المتحدة· التوظيف
  • Burke Pharmaceutical Research
    الرمز البريدي المؤكد
    هوت سبرينغز، الولايات المتحدة· نشط غير مجند
  • Doc1 Healthcare Systems
    الرمز البريدي المؤكد
    بريا، الولايات المتحدة· التوظيف
  • California Dermatology & Clinical Research Institute
    الرمز البريدي المؤكد
    إنسينيتاس، الولايات المتحدة· نشط غير مجند
  • Marvel Clinical Research
    الرمز البريدي المؤكد
    شاطئ هنتنغتون، الولايات المتحدة· نشط غير مجند
  • جامعة كاليفورنيا - إيرفين
    الرمز البريدي المؤكد
    إرفاين، الولايات المتحدة· التوظيف
  • Gavin Herbert Eye Institute
    الرمز البريدي المؤكد
    إرفاين، الولايات المتحدة· التوظيف
  • Southern California Clinical Research
    الرمز البريدي المؤكد
    سانتا آنا، الولايات المتحدة· نشط غير مجند
  • Brett King MD, LLC
    الرمز البريدي المؤكد
    فيرفيلد، الولايات المتحدة· التوظيف
  • Alliance for Multispecialty Research, LLC
    الرمز البريدي المؤكد
    فورت مايرز، الولايات المتحدة· نشط غير مجند

أسئلة شائعة

What is alopecia areata?

Alopecia areata is a condition where your immune system attacks your hair follicles, leading to patches of hair loss on your scalp, face, and sometimes other parts of your body.

ما هو الريتليسيتينيب؟

Ritlecitinib is a type of medicine designed to help calm the immune system's activity that causes hair loss in alopecia areata.

ما هو الدواء الوهمي؟

A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the real medicine's effects.

كم من الوقت سأكون في الدراسة؟

If you join, you'll be part of the study for about 13 months, with up to 9 visits to the clinic during that time.

Can I continue my other hair loss treatments?

No, if you join this study, you'll need to stop any other treatments you're currently taking for your alopecia areata.

كيفية معرفة المزيد

مركز اتصال Pfizer CT.gov

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.